The disclosure is directed to the use of rilpivirine, or a salt thereof, to treat HIV infection in pediatric subjects.

The disclosure is directed to the use of rilpivirine, or a salt thereof, to treat HIV infection in pediatric subjects.

The present invention relates to combination therapy with (a) a mutant IDH inhibitor having the Formula I and (b) one or more of an antimetabolite agent, a hypomethylating agent, and a mutant Flt3 (Flt3) inhibitor, for the treatment of cancer.

##STR00001##

The present invention relates to combination therapy with (a) a mutant IDH inhibitor having the Formula I and (b) one or more of an antimetabolite agent, a hypomethylating agent, and a mutant Flt3 (Flt3) inhibitor, for the treatment of cancer.

##STR00001##

A method of treating a pervasive development disorder in a juvenile or adolescent subject in need thereof includes administering subanesthetic doses of an NMDAR antagonist at a first dosing interval effective to alleviate at least one neurological symptom associated with the pervasive development disorder, wherein time between subanesthetic doses of the NMDAR antagonist during the first dosing interval is at least 12 hours.

A method of treating a pervasive development disorder in a juvenile or adolescent subject in need thereof includes administering subanesthetic doses of an NMDAR antagonist at a first dosing interval effective to alleviate at least one neurological symptom associated with the pervasive development disorder, wherein time between subanesthetic doses of the NMDAR antagonist during the first dosing interval is at least 12 hours.

A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

The present invention relates to combination therapy with a mutant IDH inhibitor of Formula (I) and a Bcl-2 inhibitor, for the treatment of cancer.

##STR00001##

The present invention relates to combination therapy with a mutant IDH inhibitor of Formula (I) and a Bcl-2 inhibitor, for the treatment of cancer.

##STR00001##